Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call
October 17 2007 - 8:00AM
PR Newswire (US)
Avigen to host conference call Wednesday, October 24, at 1:30 p.m.
EDT ALAMEDA, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Avigen, Inc.
(NASDAQ:AVGN), a biopharmaceutical company developing innovative
therapies for the treatment of neurological conditions, will hold
its quarterly conference call to discuss third quarter results on
Wednesday, October 24, 2007, at 1:30 p.m. EDT (10:30 a.m. PDT).
Kenneth Chahine, Chief Executive Officer, and Michael Coffee, Chief
Business Officer, can be heard by calling 888-396-2369 (U.S.) or
617-847-8710 (non-U.S. locations) using passcode 85761637. This
call is being webcast by Thomson/CCBN and can be accessed at
Avigen's website at http://www.avigen.com/. The webcast is also
being distributed through the Thomson StreetEvents Network.
Individual investors can listen to the call at
http://www.earnings.com/, Thomson's individual investor portal,
powered by StreetEvents. Institutional investors can access the
call via Thomson StreetEvents (http://www.streetevents.com/), a
password-protected event management site. A rebroadcast of the call
will be available shortly after the conclusion of the session. The
replay may be accessed over the Internet at http://www.avigen.com/
or by calling 888-286-8010 (U.S.) or 617-801-6888 (non-U.S.
locations) using passcode 67087442. About Avigen Avigen, Inc. is a
biopharmaceutical company focused on unique small molecule
therapeutics and biologics to treat serious, chronic neurological
disorders, including neuropathic pain and neuromuscular spasm and
spasticity. For press releases and other corporate information,
visit our website at http://www.avigen.com/. DATASOURCE: Avigen,
Inc. CONTACT: Michael Coffee, Chief Business Officer, Avigen, Inc.,
+1-510-748-7372, Web site: http://www.avigen.com/
Copyright
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Jul 2023 to Jul 2024